Skip to Content
Merck
All Photos(1)

Key Documents

Y0000359

Acebutolol impurity B

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

N-{3-Acetyl-4-{(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy}phenyl}acetamide, Diacetolol

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H24N2O4
CAS Number:
Molecular Weight:
308.37
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

acebutolol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C16H24N2O4/c1-10(2)17-8-14(21)9-22-16-6-5-13(18-12(4)20)7-15(16)11(3)19/h5-7,10,14,17,21H,8-9H2,1-4H3,(H,18,20)

InChI key

AWOGXJOBNAWQSF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acebutolol impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

N V Fergusson et al.
Annals of the Royal College of Surgeons of England, 67(2), 124-126 (1985-03-01)
Twenty eight patients were randomly allocated into treatment or placebo groups. The treatment group received a single 400 mg oral dose of acebutolol, the placebo group an identical inert prepation. A blood sample from each patient was subsequently analysed for
U Borchard et al.
Archives internationales de pharmacodynamie et de therapie, 273(1), 4-17 (1985-01-01)
The cardioselectivity and specificity of diacetolol, the major metabolite of the beta-adrenoceptor blocking drug acebutolol, was studied in the isolated right atrium of the guinea-pig and rat and the papillary muscle and trachea of the guinea-pig. The beta-adrenoceptor blocking potency
M S Thomas et al.
European journal of clinical pharmacology, 29(6), 679-683 (1986-01-01)
The beta-adrenergic selectivity of diacetolol, the major metabolite of acebutolol, has been compared with that of acebutolol, metoprolol and propranolol in 11 normal subjects. Bronchial and cardiac beta-adrenoceptor blockade were assessed on separate occasions after diacetolol 600 mg, acebutolol 400
M Piquette-Miller et al.
Agents and actions, 37(3-4), 290-296 (1992-11-01)
Disease states such as arthritis may interact with the kinetics of beta-blockers. Acebutolol (AC) is a chiral beta-blocker which is available as a racemate. The beneficial properties of AC, however, is attributed mainly to the S-(+)-enantiomer. The disposition of AC
M Piquette-Miller et al.
Journal of clinical pharmacology, 32(2), 148-156 (1992-02-01)
Acebutolol (AC) is a chiral beta-blocker that is metabolized to an equipotent chiral metabolite, diacetolol (DC). A stereoselective disposition of AC and DC enantiomers has recently been reported in young healthy subjects. As many physiologic properties affecting drug disposition are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service